Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome

Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome

BackgroundApolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to...

Full description

Bibliographic Details
Main Authors: Hyo-Sun Lee, Chang Hee Jung, Sung Rae Kim, Hak Chul Jang, Cheol-Young Park
Format: Article
Language:English
Published: Academya Publishing Co. 2016-03-01
Series:Endocrinology and Metabolism
Subjects:
Apolipoprotein B-48
Lp-PLA
Metabolic syndrome
Pitavastatin
Online Access:http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-31-120.pdf

Internet

http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-31-120.pdf

Similar Items